Mammary Cell News Volume 2.06 | Feb 18 2010

TOP STORY

Master Gene SRC-3 Enables Breast Cancer Growth, Invasion
The master gene called steroid receptor coactivator 3 not only enhances estrogen-dependent growth of cancer cells by activating and encouraging the transcription of a genetic message into a protein, it also sends a signal to the cell membrane to promote cell motility or movement. [Press release from the Baylor College of Medicine discussing online prepublication in Molecular Cell]

Study Reveals Genetic Link between Mammographic Density and Breast Cancer
The study revealed that certain breast cancer genetic variants increase mammographic density, confirming the link between mammographic breast density and breast cancer. [Press release from EurekAlert! discussing online prepublication in Cancer Research]

GUMC Researchers Say Flower Power May Reduce Resistance to Breast Cancer Drug Tamoxifen
Combining tamoxifen, the world’s most prescribed breast cancer agent, with a compound found in the flowering plant feverfew may prevent initial or future resistance to the drug.  [Press release from the Georgetown Lombardi Comprehensive Cancer Center discussing online prepublication in FASEB J]

LABORATORY RESEARCH

SRC-3(Delta)4 Mediates the Interaction of EGFR with FAK to Promote Cell Migration
Findings identify phosphorylated SRC-3(delta)4 as a missing adaptor between EGFR and its downstream signaling molecule FAK to coordinately regulate EGF-induced cell migration. [Mol Cell]

Vitamin D Deficiency Promotes Human Breast Cancer Growth in a Murine Model of Bone Metastasis
Study concluded that vitamin D deficiency promotes the growth of human breast cancer cells in the bones of nude mice. [Cancer Res]

An RNA Interference Screen Identifies Metabolic Regulators NR1D1 and PBP as Novel Survival Factors for Breast Cancer Cells with the ERBB2 Signature
Research showed that ERBB2-positive breast cancer cells are genetically preprogrammed to depend on NR1D1 and PBP for the energy production necessary for survival. [Cancer Res]

A Potential Tumor Suppressor Role for Hic1 in Breast Cancer Through Transcriptional Repression of Ephrin-A1
Hypermethylated in cancer 1 (HIC 1) spatially restricts ephrin-A1 expression in development, and that upregulated expression of ephrin-A1 resulting from epigenetic silencing of HIC1 in cancer cells may be an important mechanism in epithelial malignancy. [Oncogene]

BCL2 and CASP8 Regulation by NF-(kappa)B Differentially Affect Mitochondrial Function and Cell Fate in Antiestrogen-Sensitive and -Resistant Breast Cancer Cells
Data provide significant new insights into how molecular signaling affects antiestrogen responsiveness and strongly suggest that a combination of parthenolide and tamoxifen may offer a novel therapeutic approach to the management of some ER-positive breast cancers [FASEB J]

Delineating Genetic Alterations for Tumor Progression in the MCF10A Series of Breast Cancer Cell Lines
Genetic analyses uncovered sequential molecular events that delineate breast tumor progression. These events include CDKN2A deletion and MYC amplification in immortalization, HRAS activation in transformation, PIK3CA activation in the formation of malignant tumors, and RUNX1 deletion associated with poorly-differentiated malignant tumors. [PLoS One]

CLINICAL RESEARCH

Aspirin Intake and Survival After Breast Cancer
Among women living at least 1 year after a breast cancer diagnosis, aspirin use was associated with a decreased risk of distant recurrence and breast cancer death. [J Clin Oncol]

Alberta Physical Activity and Breast Cancer Prevention Trial: Sex Hormone Changes in a Year-Long Exercise Intervention Among Postmenopausal Women
This trial found that previously sedentary postmenopausal women can adhere to a moderate- to vigorous-intensity exercise program that results in changes in estradiol and sex hormone-binding globulin concentrations that are consistent with a lower risk for postmenopausal breast cancer. [ J Clin Oncol]

Multiplexed Assessment of the Southwest Oncology Group-Directed Intergroup Breast Cancer Trial S9313 by AQUA Shows That Both High and Low Levels of HER2 Are Associated with Poor Outcome
In patients who were uniformly treated with doxorubicin and cyclophosphamide chemotherapy and tamoxifen, both estrogen receptor and progesterone receptor, assessed as continuous variables, were highly prognostic, whereas p53 expression was not. [Am J Pathol]

Micrometastatic Node-Positive Breast Cancer: Long-Term Outcomes and Identification of High-Risk Subsets in a Large Population-Based Series
The number of positive nodes and the lymph node ratio should be considered in conjunction with tumor factors in risk estimates and treatment decisions for patients with nodal micrometastatic breast cancer. [Ann Surg Oncol]

Newfoundland and Labrador Breast Cancer Test Victims Win $17.5M Settlement
The Supreme Court of Newfoundland and Labrador has approved a $17.5-million settlement in a class-action lawsuit launched by hundreds of patients whose breast cancer tests were botched. [CTV News]

Safeway Gives another $317,000 for TGen Breast Cancer Research
Even with unemployment high and sales down, Safeway Inc. has donated more than $317,000 to fund breast cancer research. [Translational Genomics Research Institute Press Release]

£6 Million to be Invested in Further Regenerative Medicine Research and Development
The Technology Strategy Board is to invest a further £6 million in regenerative medicine research and development and has invited British companies to bid for funding through two new competitions. [Technology Strategy Board Press Release]

Portland Development Commission Spends $800,000 for Bioscience ‘Wet Labs’
Oregon’s biotech community will soon have access to four wet labs, where early stage companies can test and analyze chemicals and drugs. [Portland Business Journal]

Expressions of Interest for Membership of the Therapeutic Goods Committee [Therapeutic Goods Administration, Australia]

Food and Drug Administration Budget Draws Cries of ‘Not Enough’
A coalition of interests will push for more money, saying chronic underfunding has led to failures at the agency and that society, not just companies, are affected. [Food and Drug Administration, United States]

Waivers for Conflicts of Interest for the February 22, 2010 Vaccines and Related Biological Products Advisory Committee Meeting [Center for Biologics Evaluation and Research, United States]

Delays in Grant Application Submission due to Widespread Winter Storm (NOT-OD-10-061) [National Institutes of Health, United States]

Recovery Act Limited Competition: Program to Enhance National Institutes of Health-Supported Global Health Research Involving Human Subjects (S07) (RFA-OD-10-006) [National Institutes of Health, United States]

Institutional Clinical and Translational Science Award (U54) (RFA-RM-10-001) [National Institutes of Health, United States]

IACUC 101 Workshop and PRIM&R 2010 IACUC Conference: March 21-23, 2010 in Baltimore, MD (NOT-OD-10-059) [National Institutes of Health, United States]

Notice of Intent to Establish a New National Institutes of Health Common Fund Program: Library of Integrated Network-Based Cellular Signatures (LINCS) (NOT-RM-10-002) [National Institutes of Health, United States]

Investigator Initiated Multi-Site Clinical Trials (Collaborative R01) (PAR-10-096) [National Institutes of Health, United States]

Expressions of Interest for Membership of the Therapeutic Goods Committee [Therapeutic Goods Administration, Australia]

EVENTS

27th Annual Miami Breast Cancer Conference
March 3-6, 2010
Miami, United States

7th European Breast Cancer Conference (EBCC)
March 24-27, 2010
Barcelona, Spain

34th Annual Symposium of the American Society of Breast Disease (ASBD)
April 16-17, 2010,
New York City, United States

American Association for Cancer Research (AACR) 101st Annual Meeting 2010
April 17-21, 2010
Washington, DC, United States

BIT’s 3rd Annual World Cancer Congress 2010 – Breast Cancer Conference
April 25-27, 2010
Shanghai, China

IMPAKT Breast Cancer Conference
May 6-8, 2010
Brussels, Belgium

Breast Cancer Research 2010 Conference
May 18, 2010
London, United Kingdom

American Society of Clinical Oncology (ASCO) Annual Meeting 2010
June 4-8, 2010
Chicago, United States

Gordon Research Conference: Mammary Gland Biology
June 6-11, 2010
Lucca (Barga), Italy

12th Milan Breast Cancer Conference
June 16-18, 2010
Milan, Italy

The 21st Meeting of the European Association for Cancer Research (EACR)
June 26-29, 2010
Oslo, Norway

JOB OPPORTUNITIES

Manufacturing Sciences Technologist – Cell Culture (STEMCELL Technologies)

Research & Development Technologist (STEMCELL Technologies)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!